Last update 29 Nov 2024

NMS-812

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
NMS 812, NMS-03597812, NMS03597812
Target
PERK
Mechanism
PERK inhibitors(Eukaryotic initiation 2 alpha kinase 3 inhibitors)
Therapeutic Areas
NeoplasmsHemic and Lymphatic DiseasesImmune System Diseases+ [1]
Active Indication
Refractory acute myeloid leukemiaRelapsing acute myeloid leukemiaMultiple Myeloma+ [1]
Inactive Indication
Plasma cell myeloma refractoryRelapse multiple myeloma
Originator Organization
Nerviano Medical Sciences S.r.l
Active Organization
Nerviano Medical Sciences S.r.l
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with NMS-812
NCT06549790 / RecruitingPhase 1
A Phase Ia/Ib Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Including Patients With TP53 Mutations
NCT05027594 / TerminatedPhase 1
A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed or Refractory Multiple Myeloma
100 Clinical Results associated with NMS-812
Login to view more data
100 Translational Medicine associated with NMS-812
Login to view more data
100 Patents (Medical) associated with NMS-812
Login to view more data
100 Deals associated with NMS-812
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory acute myeloid leukemiaPhase 1
US
-16 Oct 2024
Relapsing acute myeloid leukemiaPhase 1
US
-16 Oct 2024
Plasma cell myeloma refractoryPhase 1
US
Nerviano Medical Sciences S.r.l
09 Sep 2022
Relapse multiple myelomaPhase 1
US
Nerviano Medical Sciences S.r.l
09 Sep 2022
Multiple MyelomaPhase 1
IT
Nerviano Medical Sciences S.r.l
27 Mar 2022
Acute Myeloid LeukemiaPreclinical
IT
Nerviano Medical Sciences S.r.l
26 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free